Conduit Pharmaceuticals EBITDA vs. Net Income
Conduit Pharmaceuticals' market capitalization and book value each provide useful but distinct information about the business. Intrinsic value for Conduit Pharmaceuticals synthesizes operating data into a single estimate that complements price and book value. Valuation methods compare these perspectives to frame context.
Note that Conduit Pharmaceuticals' intrinsic value and market price are different measures derived from different inputs. For Conduit Pharmaceuticals, key inputs include revenue of 2.72 B.
Conduit Pharmaceuticals Net Income vs. EBITDA Fundamental Analysis
Peer-based valuation metrics position Conduit Pharmaceuticals within its sector hierarchy. Conduit Pharmaceuticals stands at number one for ebitda across the peer group. It also stands at number one for net income across the peer group reflecting a 0.75 ratio of Net Income to EBITDA. Conduit Pharmaceuticals's EBITDA exceeds Net Income by a factor of 1.33 . At present, EBITDA is showing a rebounding trajectory relative to prior years. The prior-year reading for EBITDA was 315.69 Million. Comparative earnings metrics contextualize Conduit Pharmaceuticals.Conduit Net Income vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company's operating cash flow based on data from the company's income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Conduit Pharmaceuticals |
| = | 315.69 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Conduit Pharmaceuticals |
| = | 237.52 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Conduit Net Income Comparison
Conduit Pharmaceuticals is currently under evaluation for net income across the peer group.
Conduit Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Conduit Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Conduit Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Conduit Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Conduit Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | -97.2 M | -92.3 M | |
| Operating Income | 315.7 M | 331.5 M | |
| Net Loss | -16 M | -15.2 M | |
| Income Before Tax | 266.9 M | 280.2 M | |
| Total Other Income Expense Net | -48.8 M | -46.4 M | |
| Net Income | 237.5 M | 249.4 M | |
| Income Tax Expense | -29.3 M | -27.9 M | |
| Net Interest Income | -1.3 M | -1.3 M | |
| Interest Income | 14.9 K | 15.8 K | |
| Net Income Per Share | 6.00 | 6.30 | |
| Income Quality | 1.49 | 2.81 | |
| Net Income Per E B T | 0.80 | 0.84 |
Conduit Profitability Driver Comparison
Profitability drivers for Conduit Pharmaceuticals are the financial and operational factors with the greatest impact on its earnings. Investors must anticipate a wide variety of external disruptions that can affect Conduit Pharmaceuticals' profit margins, market performance, and overall investment attractiveness.
Earnings per Share Projection vs Actual
Use Conduit Pharmaceuticals in pair-trading
Pair trading with Conduit Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. Used properly, pair trading is less about prediction in isolation and more about identifying relative mispricing between related positions.
Conduit Pharmaceuticals Pair Trading
Conduit Pharmaceuticals Pair Trading Analysis
The information in the correlation table below can inform Conduit Pharmaceuticals tax-loss harvesting decisions, showing which instruments historically move in lockstep with Conduit Pharmaceuticals and can serve as viable temporary replacements.
Negative correlation assets provide natural hedges against Conduit Pharmaceuticals positions. When Conduit Pharmaceuticals's value declines, a negatively correlated instrument tends to rise, partially offsetting portfolio losses.
The combination of Correlation analysis and pair analysis offers hedging context for Conduit Pharmaceuticals. Cross-sector pair evaluation can broaden the hedging context for Conduit Pharmaceuticals. Pair trading frameworks rely on historical co-movement patterns that may not persist.Use Investing Themes to Complement your Conduit Pharmaceuticals position
Market capitalization should still be reviewed beside revenue, debt, and cash-flow quality. A theme workflow around Conduit Pharmaceuticals gives investors a structured way to compare related instruments before allocating. The resulting theme around Conduit Pharmaceuticals can be tuned for upside participation or tighter downside control depending on objectives.
Did You Try This Idea?
Run Conservative Funds Thematic Idea Now
Conservative Funds
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 40 constituents at this time.
Explore the Conservative Funds Theme as a thematic allocation that can be optimized for return targets or risk constraints.
| View All Next | Launch |
Additional Tools for Conduit Stock Analysis
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |